Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ONCT

Oncternal Therapeutics Inc

Dec 02 • 04:00PM ET

0.5266

Dollar change 0.0000
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: TGTX FATE IKT BPMC KURA IMTX RVMD NKTR AFMD

| Held by: VTI VXF IWM IWO IWC ITOT IWV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-11.69	Insider Own	10.55%	Shs Outstand	2.96M	Perf Week	-53.81%
Market Cap	1.56M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.65M	Perf Month	-63.93%
Income	-34.58M	PEG	-	EPS next Q	-	Inst Own	12.07%	Short Float	0.54%	Perf Quarter	-87.12%
Sales	2.16M	P/S	0.72	EPS this Y	-	Inst Trans	-20.42%	Short Ratio	0.10	Perf Half Y	-94.00%
Book/sh	3.09	P/B	0.17	EPS next Y	-	ROA	-117.61%	Short Interest	0.01M	Perf Year	-92.69%
Cash/sh	4.92	P/C	0.11	EPS next 5Y	0.00%	ROE	-149.86%	52W Range	0.53 - 13.14	Perf YTD	-95.09%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.19%	ROI	-377.95%	52W High	-95.99%	Beta	1.20
Dividend TTM	-	Quick Ratio	2.39	Sales past 5Y	-9.91%	Gross Margin	21.98%	52W Low	0.00%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	2.39	EPS Y/Y TTM	18.53%	Oper. Margin	-1664.00%	RSI (14)	25.19	Volatility	20.68% 14.12%
Employees	27	Debt/Eq	0.02	Sales Y/Y TTM	227.92%	Profit Margin	-1599.95%	Recom	3.00	Target Price	2.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	14.51%	Payout	-	Rel Volume	0.00	Prev Close	0.53
Sales Surprise	276.94%	EPS Surprise	4.72%	Sales Q/Q	175.98%	Earnings	Nov 07	Avg Volume	138.72K	Price	0.53
SMA20	-52.91%	SMA50	-59.05%	SMA200	-90.96%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-07-21	Initiated	Oppenheimer	Outperform	$14
Feb-23-21	Initiated	Northland Capital	Outperform	$21

Oct-22-24 09:00AM	Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire) -18.61%
Sep-12-24 09:00AM	Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives (GlobeNewswire) -59.09%
Aug-08-24 04:01PM	Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 04:05PM	Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results (GlobeNewswire) -11.54%
Jul-15-24 08:00AM	Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
04:05PM	Loading…
Jul-11-24 04:05PM	Oncternal Therapeutics to Present in JonesTrading Healthcare Summit (GlobeNewswire) +5.79%
May-30-24 04:05PM	Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
May-10-24 12:40PM	Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q1 2024 Earnings Call Transcript (Insider Monkey) -5.28%
May-09-24 08:58PM	ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:20PM	Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results (GlobeNewswire)
May-08-24 12:00PM	All You Need to Know About Oncternal Therapeutics (ONCT) Rating Upgrade to Buy (Zacks)
May-02-24 04:05PM	Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results (GlobeNewswire) +6.00%
May-01-24 09:00AM	Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-25-24 10:02AM	Oncternal Therapeutics (ONCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
09:00AM	Loading…
Apr-18-24 09:00AM	Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
Apr-14-24 12:51PM	5 Buy-Rated Stocks with Latest Insider Purchases (Insider Monkey)
Apr-10-24 04:42PM	10 Underperforming Stocks Insiders are Buying (Insider Monkey)
Mar-15-24 09:00AM	Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer (GlobeNewswire)
Mar-08-24 10:26AM	Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-07-24 09:54PM	ONCT Stock Earnings: Oncternal Therapeutics Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:01PM	Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-29-24 04:05PM	Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +7.85%
Feb-06-24 04:30PM	Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-01-24 09:00AM	Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-24 09:00AM	Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire) +5.08%
Jan-04-24 09:00AM	Oncternal Therapeutics Announces Reverse Stock Split (GlobeNewswire) -24.49%
Jan-02-24 09:00AM	Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-28-23 11:04AM	Oncternal Therapeutics reports patient death in CAR-T dose-escalation study (FierceBiotech.com) -12.42%
Dec-26-23 09:00AM	Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma (GlobeNewswire)
11:06AM	Loading…
Nov-11-23 11:06AM	Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:01PM	Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results (GlobeNewswire) -9.07%
Nov-02-23 04:05PM	Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results (GlobeNewswire) +8.83%
Oct-26-23 09:00AM	Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
Oct-25-23 09:00AM	Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (GlobeNewswire)
Oct-05-23 04:01PM	Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
Sep-07-23 09:00AM	Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board (GlobeNewswire)
Aug-10-23 04:01PM	Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results (GlobeNewswire) -6.71% -7.35%
Aug-03-23 04:30PM	Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results (GlobeNewswire) -6.65%
04:05PM	Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer (GlobeNewswire)
Jul-26-23 01:30PM	Northland Capital Markets Institutional Investor Conference (ACCESSWIRE)
Jun-30-23 04:30PM	Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-23 04:01PM	Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma (GlobeNewswire)
May-31-23 05:00PM	Oncternal Therapeutics to Participate at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-06-23 08:14AM	Oncternal Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS In Line (Simply Wall St.)
May-04-23 04:01PM	Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results (GlobeNewswire)
Apr-27-23 05:00PM	Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results (GlobeNewswire) +6.62%
Apr-17-23 06:54AM	Daily Vickers Top Buyers & Sellers for 04/17/2023 (Argus Research) +14.57%
Apr-13-23 05:00PM	Oncternal Therapeutics Participating in Oppenheimer & Co.s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors (GlobeNewswire) +9.81%
Apr-03-23 04:01PM	Oncternal Therapeutics Announces Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025 (GlobeNewswire) -56.92%
Mar-27-23 09:00AM	Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.39%
Mar-11-23 03:14AM	Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-09-23 04:01PM	Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -15.37%
Mar-02-23 05:00PM	Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) +5.34%
Mar-01-23 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-01-23 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-04-23 04:05PM	Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of Directors (GlobeNewswire)
Jan-03-23 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-10-22 03:00PM	Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022 (GlobeNewswire)
Dec-01-22 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-14-22 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.21%
Nov-03-22 04:01PM	Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results (GlobeNewswire) -9.53%
09:05AM	Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022 (GlobeNewswire)
Oct-27-22 05:53PM	Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-03-22 05:30PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.80% +14.42%
04:31PM	Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B Cell Lymphoma (GlobeNewswire)
Sep-27-22 09:00AM	Oncternal Therapeutics Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL (GlobeNewswire)
Sep-23-22 09:00AM	Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology & HemeOnc Conference (GlobeNewswire)
Sep-07-22 05:00PM	Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-09-22 04:05PM	Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-02-22 05:00PM	Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-26-22 07:34AM	The past three years for Oncternal Therapeutics (NASDAQ:ONCT) investors has not been profitable (Simply Wall St.)
Jul-14-22 04:01PM	Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCL (GlobeNewswire)
Jun-10-22 04:30PM	Oncternal Therapeutics Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress (GlobeNewswire) -13.99% -9.76%
09:00AM	Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress (GlobeNewswire)
Jun-02-22 09:00AM	Oncternal Therapeutics to Participate in the Jefferies Healthcare Conference 2022 (GlobeNewswire)
Jun-01-22 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.41%
May-26-22 05:15PM	Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022 (GlobeNewswire) +88.08%
May-17-22 07:40AM	Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation (Simply Wall St.) +12.90%
May-05-22 04:01PM	Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results (GlobeNewswire) -7.27%
May-02-22 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +23.05%
Apr-28-22 05:00PM	Oncternal Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results (GlobeNewswire) -5.25%
03:02PM	Oncternal Therapeutics (ONCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-13-22 08:30AM	Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle Cell Lymphoma (GlobeNewswire)
Apr-01-22 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.93%
Mar-10-22 04:01PM	Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire) -8.33%
Mar-07-22 05:00PM	Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-01-22 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-22 10:11AM	Oncternal Therapeutics (NASDAQ:ONCT) investors are sitting on a loss of 75% if they invested a year ago (Simply Wall St.)
Jan-20-22 04:05PM	Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies and Prostate Cancer (GlobeNewswire) -5.83%
Jan-19-22 05:38PM	Traverso Chambers Private Wealth Management, LLC Buys WisdomTree U.S. ... (GuruFocus.com)
Jan-04-22 04:01PM	Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma (GlobeNewswire)
Dec-14-21 08:53AM	Is Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Popular Amongst Institutions? (Simply Wall St.)
Dec-13-21 08:00AM	Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2021 (GlobeNewswire) -7.25%
Dec-01-21 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.08%
Nov-15-21 08:00AM	Oncternal Therapeutics Presented Updated Interim Phase 1/2 Clinical Trial Data for ONCT-216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2021 Virtual Annual Meeting (GlobeNewswire)
Nov-09-21 05:00PM	Oncternal Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference (GlobeNewswire) -5.25%
Nov-04-21 04:05PM	Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results (GlobeNewswire) +6.54%
Nov-03-21 05:00PM	Oncternal Therapeutics Joins Karolinska Institutets NextGenNK Competence Center for the Development of Next Generation NK Cell-Based Cancer Immunotherapies (GlobeNewswire)
Nov-02-21 05:00PM	Oncternal Therapeutics Announces Formation of Cell Therapy Scientific Advisory Board (GlobeNewswire)

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Yazji Salim	Officer	Oct 14 '24	Proposed Sale	1.07	4,681	5,009		Oct 15 12:12 PM
Wills Robert James	Director	Apr 08 '24	Buy	8.96	3,086	27,655	10,000	Apr 10 08:38 PM
Wills Robert James	Director	Mar 28 '24	Buy	8.48	6,914	58,602	6,914	Apr 01 07:00 PM
HALE DAVID F	Director	Feb 23 '24	Buy	9.04	714	6,455	714	Feb 27 05:03 PM
HALE DAVID F	Director	Feb 23 '24	Buy	9.04	266	2,405	29,673	Feb 27 05:03 PM
Wills Robert James	Director	Feb 23 '24	Sale	9.04	980	8,859	0	Feb 27 05:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ONCT

Oncternal Therapeutics Inc

Upgrade your FINVIZ experience